OUTLOOK THERAPEUTICS
Price & Volume
Stats
See more52W Range | $0.38-$3.39 |
Market Cap | $31.8M |
Shares Short | 4M |
Financials
See moreRevenue (12 Mos) | $205,702 |
Revenue Growth (YoY) | 658.3% |
Gross Profit (12 Mos) | -$22.3M |
Diluted EPS | -$2.89 |
News
See moreYahoo Finance • 11 days ago
Outlook Therapeutics Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update
Yahoo Finance • 2 months ago
Outlook Therapeutics drops 80% on CRL for BLA for wet AMD asset
Yahoo Finance • 2 months ago
Outlook Therapeutics Provides Regulatory Update on U.S. Food and Drug Administration Review of ONS-5010/LYTENAVA™ (bevacizumab-vikg) for the Treatment of Wet AMD
Yahoo Finance • 3 months ago
Outlook Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference
About
CEO | Mr. Robert Charles Jahr |
CFO | Mr. Lawrence A. Kenyon CPA |
Address | 111 S. Wood Avenue, Iselin, NJ, United States, 08830 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 17 |
